logo
  

Aegon To Sell Businesses In Czech Republic, Slovakia For 155 Mln Euros

Financial services company Aegon NV (AGN.L,AEG) said Thursday that it has agreed to sell its businesses in Czech Republic and Slovakia to NN Group for 155 million euros, in line with its strategic objective to optimize its portfolio and capital allocation across its businesses.

The sale, which is subject to customary regulatory approvals, is expected to close early 2019 and will have no material impact on Aegon's other operations in Central & Eastern Europe. The proceeds from the divestment will be upstreamed to the group.

As a result of the transaction, Aegon's group solvency ratio is estimated to improve by about 1%-point. Based on the book value as of December 31, 2017 and taking into account dividends paid in 2018, the book gain is expected to amount to about 80 million euros, and will be reported in other income.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT